Stylus Colour 300 / 400 / 440 / 460 / 480 / 480sxu / 580 / 600 / 640 / 660 / 670 / 680 / 700 / 740 / 760 / 777 / 800 / 850 / 860 / 900 / 980 / 1160 / 1520 / C20 / C40 / C42 / C42UX / C44 / C46 / C44UX / C60 / C61 / C62 / C63 / CX3100 / CX3200 / RX400 / RX420Stylus Photo 750 / 780 / 785EPX / 790 / 810 / 820 / 830 / 830U / 870 / 870LE / 875DC / 875DCS / 890 / 895 / 900 / 915 / 925 / 935 / 950 / 980 / 1270 / 1280 / 1290 / Photo / Ex / 1200 / R200 / R300 / RX500 / RX600 / R265 / R285 / Remember all ink is not the same - call for advice and a quote for the correct ink for your printer(s) - "Universal" is generally OK for older technology bubblejet printers does not always match the original and may give a poorer result.
Continued use of panitumumab is considered not medically necessary for persons whose disease has progressed with panitumumab or who have developed intolerance to this drug.
They were stratified into 2 strata (high or low staining intensity) and received intravenous panitumumab 2.5 mg/kg of body weight weekly 8 of every 9 weeks until disease progression or unacceptable toxicity.
Panitumumab (Vectibix) is a human monoclonal antibody that blocks the extra-cellular domain of the EGFR, and has not been associated with the formation of antibodies directed against it (Saadeh and Lee, 2007).
EGFR is a transmembrane glycoprotein that is constitutively expressed in many normal epithelial tissues, including the skin and hair follicle.
Aetna considers panitumumab experimental and investigational for persons who have had clinical failure (disease progression) on cetuximab (Erbitux) because there is insuficient evidence to support the use of panitumumab after clinical failure on cetuximab.
Use of panitumumab with bevacizumab (Avastin), erlotinib (Tarceva), or gefitinib (Iressa)considered experimental and investigational because the effectiveness of these drugs in combination has not been established.